title: Treatment of canine non-indolent T cell lymphoma using the VELCAP-TSC protocol: A retrospective evaluation of 70 dogs (2003-2013).
abstract: The immunophenotype of canine non-indolent lymphoma has prognostic value; dogs with T cell lymphoma have a poorer response rate and shorter survival times than dogs with B cell lymphoma. This study sought to retrospectively evaluate prognostic factors for complete remission (CR), progression free survival (PFS) and overall survival time (OST) in 70 dogs with T cell lymphoma treated with an alkylator-rich, combination protocol. The overall remission was 72.9%; 45 dogs (64.3%) achieved CR and six (8.6%) achieved partial remission. Dogs that were neutropenic at diagnosis were significantly more likely to achieve CR. The median overall PFS was 175 days; 1, 2 and 3 year PFS were 26.8%, 15.8%, and 12.6%, retrospectively, after commencing chemotherapy. Median PFS was significantly longer for dogs that achieved CR. Median OST was 237 days. The 1, 2 and 3 year survival rates were 31%, 20.2% and 11.5%, retrospectively, after commencing chemotherapy. The median OST was significantly longer for dogs that achieved CR and significantly shorter for Boxers and those in substage b at diagnosis. More than 30% of dogs treated with this protocol survived >1 year, suggesting that favourable outcomes and longer survival are possible for a proportion of dogs with T cell lymphoma.
authors.affiliation: Animal Referral Hospital, 250 Parramatta Rd, Homebush West, NSW 2140, Australia; Aussie Paws, Suite 1, Level 3, 90 Mount Street, North Sydney, NSW 2060, Australia.
authors.forename: Ingrid H
authors.initials: IH
authors.lastname: Goodman
authors.affiliation: Animal Referral Hospital, 250 Parramatta Rd, Homebush West, NSW 2140, Australia; Veterinary Oncology Consultants, 379 Lake Innes Drive, Wauchope 2446, NSW, Australia. Electronic address: voc@vetoncologyconsults.com.
authors.forename: Antony S
authors.initials: AS
authors.lastname: Moore
authors.affiliation: Animal Referral Hospital, 250 Parramatta Rd, Homebush West, NSW 2140, Australia; Veterinary Oncology Consultants, 379 Lake Innes Drive, Wauchope 2446, NSW, Australia.
authors.forename: Angela E
authors.initials: AE
authors.lastname: Frimberger
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D018572:Disease-Free Survival; D004283:Dog Diseases / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality*; D004285:Dogs; D005260:Female; D016399:Lymphoma, T-Cell / Q000175:diagnosis / Q000188:drug therapy / Q000401:mortality / Q000662:veterinary*; D008297:Male; D011379:Prognosis; D012074:Remission Induction; D012189:Retrospective Studies; D015996:Survival Rate
chemical_list: D000970:Antineoplastic Agents
keywords: Canine; Chemotherapy; Neutropenia; Oncology; T cell lymphoma